🇺🇸 FDA
Patent

US 10570393

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K47/549

Quick answer

US patent 10570393 (Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61K, A61K31/713, A61K47/549, A61P, A61P3/06